Investment Opportunities
We are seeking investors to fund the clinical development of this groundbreaking vaccine. There are several opportunities to get involved:
- Co-development Partnerships
- Licensing Agreements
- Spin-off Creation
Your investment could accelerate the vaccine candidate to a Phase Ib/IIa clinical trial in C9orf72 ALS/FTD patients. A successful Phase IIb clinical trial could allow direct entry into the orphan drug market.
Invest in the Future of ALS Treatment
The German Center for Neurodegenerative Diseases (DZNE) and Intravacc B.V. have received funding from the European Union (EIC Transition Grant) for the pre-clinical development of a prototype vaccine for Amyotrophic Lateral Sclerosis (ALS) caused by the C9orf72 mutation. This project, known as GA-VAX, aims to develop the vaccine to a stage where it can be clinically tested in humans.
With promising preclinical results, including a GLP toxicology study, we will be ready to move the vaccine towards clinical trials and, ultimately, market approval.
Get in Touch
Review our factsheet or contact us directly to arrange a meeting for an update on the current status of development. We are eager to discuss your potential business interest and present our non-confidential slide deck (with a confidential version available under CDA).
Join us in revolutionizing ALS treatment. Invest in GA-VAX today.
Contact: bd(at)intravacc.nl